Cue Biopharma, Inc.

CUENASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
29.46 USD
↘ 0.18 (0.61%)AT CLOSE (11:59 AM EDT)
29.27
↘ 0.19 (0.63%)
POST MARKET (AS OF 06:53 PM EDT)
Post Market
AS OF 06:53 PM EDT
29.27
↘ 0.19 (0.63%)
🔴Market: CLOSED
Open?$28.40
High?$30.00
Low?$26.01
Prev. Close?$29.64
Volume?92.2K
Avg. Volume?963.3K
VWAP?$27.88
Rel. Volume?0.10x
Bid / Ask
Bid?$23.54 × 100
Ask?$33.99 × 100
Spread?$10.45
Midpoint?$28.77
Valuation & Ratios
Market Cap?123.7M
Shares Out?4.2M
Float?94.7M
Float %?97.2%
P/E Ratio?N/A
P/B Ratio?5.73
EPS?-$4.65
Dividend?0.00%
Ex-Dividend?N/A

CUE is currently priced at $29.46. Our models show a "Strong Buy" technical signal alongside a "Neutral" fundamental rating. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On valuation, CUE trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Immunology & Autoimmune
Employees
29
Market Cap
123.7M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.cuebiopharma.com
Listed
2018-01-02
Address
40 GUEST STREET
BOSTON, MA 02135
Phone: 617-949-2680
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
0
Momentum?
77
Short Sent.?
75
Piotroski F-Score?2/9Weak
Altman Z-Score?-9.22Distress
Confidence?48%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?0.27%Low
Short Interest?255.2K
Days to Cover?1.0
Free Float94.7M
Avg Daily Volume2.0M
Settlement Date2026-05-15
Financial Health
Current Ratio?3.57Strong
Quick Ratio?3.57Strong
Cash Ratio?2.22Strong
Debt/Equity?0.05Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
75/100
P/E?
N/A▾
P/B?
Peers
100
S&P
32
5.73FAIR▾
P/S?
Peers
100
S&P
40
3.78FAIR▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-6.0CHEAP▾
EV/Sales?
Peers
100
S&P
56
3.31FAIR▾
Returns & Efficiency
ROE?
S&P
3
-90.4%WEAK▾
ROA?
S&P
3
-63.2%WEAK▾
Cash Flow & Enterprise
FCF?$-24605000
Enterprise Value?$108.4M
Fundamentals ratios updated end of day
MarketsMoversWatchlist